(May 26, 2020, 2:08 PM EDT) -- CHICAGO — After a testosterone replacement therapy plaintiff complained that common benefit fees and his attorney’s contingency fee “left him owing money,” the Illinois federal judge overseeing the testosterone multidistrict litigation on May 21 ordered the Plaintiffs’ Steering Committee (PSC) to recommend whether the common benefit fee should be reduced or waived (In Re: Testosterone Replacement Therapy Products Liability Litigation, MDL Docket No. 2545, No. 14-cv-1748, N.D. Ill., E. Div.)....